专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 外观设计

USD744907S1 Scooter 有权
公开(公告)号：USD744907S1
公开(公告)日：2015-12-08
申请号：US29508628
申请日：2014-11-07
申请人： Jordan Mielke , Terry Richards , Stephen Price
设计人： Jordan Mielke , Terry Richards , Stephen Price

2. 发明授权

US08815895B2 Mediators of hedgehog signaling pathways, compositions and uses related hereto 有权
标题翻译：刺猬信号通路的调解者，组合物和用途相关
公开(公告)号：US08815895B2
公开(公告)日：2014-08-26
申请号：US13421899
申请日：2012-03-16
申请人： Oivin M. Guicherit , Edward Andrew Boyd , Shirley Ann Brunton , Stephen Price , John Harry Alexander Stibbard , Colin H. Mackinnon
发明人： Oivin M. Guicherit , Edward Andrew Boyd , Shirley Ann Brunton , Stephen Price , John Harry Alexander Stibbard , Colin H. Mackinnon
IPC分类号： A61K31/4427
CPC分类号： A61K31/4427 , C07D401/10 , C07D401/12 , C07D401/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D491/04
摘要： The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
摘要翻译：本发明提供用于抑制由刺猬获得功能，功能丧失功能或平滑增益功能引起的异常生长状态的可用方法和试剂，包括使细胞与式（I）的刺猬蛋白拮抗剂在足够量的异常生长状态，例如，激发正常的ptc途径或拮抗平滑或刺猬活性。

3. 发明授权

US08697693B2 Pharmaceutical compounds 失效
标题翻译：药物化合物
公开(公告)号：US08697693B2
公开(公告)日：2014-04-15
申请号：US13553650
申请日：2012-07-19
申请人： Stewart James Baker , Paul John Goldsmith , Timothy Colin Hancox , Neil Anthony Pegg , Stephen Price , Stephen Joseph Shuttleworth , Sukhjit Sohai
发明人： Stewart James Baker , Paul John Goldsmith , Timothy Colin Hancox , Neil Anthony Pegg , Stephen Price , Stephen Joseph Shuttleworth , Sukhjit Sohai
IPC分类号： A61K31/535 , C07D413/14
CPC分类号： C07D495/04
摘要： Thienopyrimidines of formula (Ia) or (Ib): wherein R1-R3 have any of the values described herein, and the pharmaceutically acceptable salt thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase, in particular the p110 delta subtype, such as immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.
摘要翻译：式（Ia）或（Ib）的噻吩并嘧啶：其中R1-R3具有本文所述的任何值，并且其药学上可接受的盐具有作为PI3K抑制剂的活性，因此可用于治疗由异常细胞生长引起的疾病和障碍，与PI3激酶，特别是p110δ亚型相关的功能或行为，例如免疫疾病，心血管疾病，病毒感染，炎症，代谢/内分泌障碍和神经障碍。还描述了合成化合物的方法。

4. 发明授权

US08673952B2 Benzoxepin PI3K inhibitor compounds and methods of use 有权
标题翻译：苯并西林PI3K抑制剂化合物及其使用方法
公开(公告)号：US08673952B2
公开(公告)日：2014-03-18
申请号：US13568707
申请日：2012-08-07
申请人： Nicole Blaquiere , Steven Do , Danette Dudley , Adrian Folkes , Richard Goldsmith , Robert Heald , Timothy Heffron , Aleksandr Kolesnikov , Chudi Ndubaku , Alan G. Olivero , Stephen Price , Steven Staben , BinQing Wei
发明人： Nicole Blaquiere , Steven Do , Danette Dudley , Adrian Folkes , Richard Goldsmith , Robert Heald , Timothy Heffron , Aleksandr Kolesnikov , Chudi Ndubaku , Alan G. Olivero , Stephen Price , Steven Staben , BinQing Wei
IPC分类号： A61K31/41 , C07D249/14
CPC分类号： C07D495/04 , A61K31/381 , A61K31/41 , A61K31/4196 , A61K31/4245 , A61K31/429 , A61K31/4365 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , C07D249/14 , C07D495/14 , C07D513/04 , C07D513/14
摘要： Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式I的苯并氧杂多磷化合物，包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢产物及其药学上可接受的盐可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗诸如由脂质激酶介导的癌症。公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

5. 发明授权

US08606502B2 Navigation device and method 有权
标题翻译：导航装置和方法
公开(公告)号：US08606502B2
公开(公告)日：2013-12-10
申请号：US12736878
申请日：2008-12-29
申请人： Stephen Price Hixson
发明人： Stephen Price Hixson
IPC分类号： G01S1/00
CPC分类号： G01C21/3644
摘要： A navigation device includes a locator for determining a location of the navigation device, a processor, an audio output device and/or a display controllable by the processor, and a store for map data and historical data. The historical data includes historical information about a location and a location identifier identifying the location. The processor is arranged to control the audio output device and/or display to convey the historical information as an audio and/or visual output in response to the processor determining from the locator that the navigation device is in the vicinity of the location identified by the location identifier.
摘要翻译：导航装置包括用于确定导航装置的位置的定位器，处理器，音频输出装置和/或可由该处理器控制的显示器，以及用于地图数据和历史数据的商店。历史数据包括关于位置的历史信息和标识位置的位置标识符。处理器被布置成控制音频输出设备和/或显示器以响应于处理器从定位器确定导航设备在由该位置识别的位置附近的位置附近，将历史信息作为音频和/或视觉输出传达位置标识符

6. 发明授权

US08492427B2 Isoindolones derivatives as MEK kinase inhibitors and methods of use 失效
标题翻译：异吲哚酮衍生物作为MEK激酶抑制剂和使用方法
公开(公告)号：US08492427B2
公开(公告)日：2013-07-23
申请号：US12998000
申请日：2009-07-01
申请人： Emanuela Gancia , Robert Andrew Heald , Philip Jackson , Stephen Price
发明人： Emanuela Gancia , Robert Andrew Heald , Philip Jackson , Stephen Price
IPC分类号： A61K31/437 , A61K31/4035 , A61K31/416 , A61K31/4985 , C07D231/54 , C07D241/00 , C07D221/00 , C07D209/44
CPC分类号： C07D209/46
摘要： The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
摘要翻译：本发明涉及具有抗癌和/或抗炎活性的具有式（I）的异吲哚酮，更具体地涉及MEK激酶抑制活性。本发明提供了可用于抑制异常细胞生长，治疗过度增殖性疾病或治疗哺乳动物炎性疾病的组合物和方法。本发明还涉及将化合物用于体外，原位和体内诊断或治疗哺乳动物细胞或相关病理状况的方法。

7. 发明申请

US20130012488A1 BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE 有权
标题翻译：苯并吡喃PI3K抑制剂化合物及其使用方法
公开(公告)号：US20130012488A1
公开(公告)日：2013-01-10
申请号：US13568707
申请日：2012-08-07
申请人： Nicole Blaquiere , Steven Do , Danette Dudley , Adrian Folkes , Richard Goldsmith , Robert Heald , Timothy Heffron , Aleksandr Kolesnikov , Chudi Ndubaku , Alan G. Olivero , Stephen Price , Steven Staben , BinQing Wei
发明人： Nicole Blaquiere , Steven Do , Danette Dudley , Adrian Folkes , Richard Goldsmith , Robert Heald , Timothy Heffron , Aleksandr Kolesnikov , Chudi Ndubaku , Alan G. Olivero , Stephen Price , Steven Staben , BinQing Wei
IPC分类号： A61K31/429 , C07D495/04 , A61P35/00 , C07D495/14 , A61K31/4365 , A61K31/5377 , C07D513/04 , A61K31/381
CPC分类号： C07D495/04 , A61K31/381 , A61K31/41 , A61K31/4196 , A61K31/4245 , A61K31/429 , A61K31/4365 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , C07D249/14 , C07D495/14 , C07D513/04 , C07D513/14
摘要： Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式I的苯并氧杂多磷化合物，包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢产物及其药学上可接受的盐可用于抑制脂质激酶，包括p110α和PI3K的其他同种型，并用于治疗诸如由脂质激酶介导的癌症。公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

8. 发明授权

US08293735B2 Thienopyrimidine derivatives as P13K inhibitors 失效
标题翻译：噻吩并嘧啶衍生物作为P13K抑制剂
公开(公告)号：US08293735B2
公开(公告)日：2012-10-23
申请号：US12739435
申请日：2008-10-27
申请人： Timothy Colin Hancox , Neil Anthony Pegg , Alan John Nadin , Stephen Price
发明人： Timothy Colin Hancox , Neil Anthony Pegg , Alan John Nadin , Stephen Price
IPC分类号： A61K31/535 , C07D413/14
CPC分类号： C07D495/04 , C07D519/00
摘要： Thienopyrimidines of formula (I) wherein W and R1 to R4 are as defined in the claims, and the pharmaceutically acceptable salts thereof are inhibitors of PI3K and are selective for the p110δ isoform, which is a class Ia PI3 kinase, over both other class Ia and class Ib kinases. The compounds may be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
摘要翻译：其中W和R 1至R 4如权利要求中所定义的式（I）的噻吩并嘧啶及其药学上可接受的盐是PI3K的抑制剂，并且对于作为Ia类PI3激酶的p110δ同种型，对于其它1a类和1b类激酶。该化合物可用于治疗与PI3激酶例如癌症，免疫疾病，心血管疾病，病毒感染，炎症，代谢/内分泌功能障碍和神经障碍相关的异常细胞生长，功能或行为引起的疾病和障碍。

9. 发明申请

US20120202785A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE 失效
标题翻译：杂环化合物和使用方法
公开(公告)号：US20120202785A1
公开(公告)日：2012-08-09
申请号：US13369016
申请日：2012-02-08
申请人： Robert Heald , Stephen Price , Brian Safina , Pascal Pierre Alexandre Savy , Eileen Mary Seward , Daniel P. Sutherlin , Bohdan Waszkowycz
发明人： Robert Heald , Stephen Price , Brian Safina , Pascal Pierre Alexandre Savy , Eileen Mary Seward , Daniel P. Sutherlin , Bohdan Waszkowycz
IPC分类号： A61K31/52 , C07D519/00 , C07D487/04 , C07D495/04 , C07D403/12 , C07D498/06 , A61K31/519 , A61K31/5377 , A61P35/00 , A61P37/00 , A61P9/00 , A61P31/12 , A61P29/00 , A61P3/00 , A61P5/00 , A61P25/00 , A61P19/02 , A61P37/08 , A61P1/04 , A61P11/06 , A61P17/06 , A61P35/02 , C07D473/34
CPC分类号： C07D473/34 , A61K31/519 , A61K31/52 , A61K31/5377 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D471/04 , C07D473/16 , C07D473/32 , C07D473/40 , C07D487/04 , C07D495/04 , C07D498/06 , C07D513/04 , C07D519/00
摘要： Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式I化合物，包括立体异构体，几何异构体，互变异构体，代谢物及其药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学障碍和癌症介导的病症。公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

10. 发明申请

US20120178736A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE 失效
标题翻译：用于P110 DELTA的双相PYRIMIDIN PI3K抑制剂化合物选择及使用方法
公开(公告)号：US20120178736A1
公开(公告)日：2012-07-12
申请号：US13427081
申请日：2012-03-22
申请人： Georgette Castanedo , Bryan Chan , David Goldstein , Rama Kondru , Matthew Lucas , Wylie Palmer , Stephen Price , Brian Safina , Pascal Pierre Alexandre Savy , Eileen Mary Seward , Daniel P. Sutherlin , Zachary K. Sweeney
发明人： Georgette Castanedo , Bryan Chan , David Goldstein , Rama Kondru , Matthew Lucas , Wylie Palmer , Stephen Price , Brian Safina , Pascal Pierre Alexandre Savy , Eileen Mary Seward , Daniel P. Sutherlin , Zachary K. Sweeney
IPC分类号： A61K31/5377 , C07D487/04 , A61P29/00 , A61P37/00 , A61P37/06 , A61P37/08 , A61P1/04 , A61P1/00 , A61P17/00 , A61P11/06 , A61P19/04 , A61P25/00 , A61P7/02 , A61P7/00 , A61P11/00 , A61P17/06 , A61P19/02 , C07D495/04
CPC分类号： C07D513/04 , C07D487/04 , C07D491/04 , C07D495/04
摘要： Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is 0, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式（I）和（Ib）化合物，其中（i）X1为N，X 2为S，（ii）X1为CR7，X2为S，（iii）X1为N，X2为NR2，或（iv）X1为CR7， X 2为0，包括立体异构体，互变异构体，代谢物和药学上可接受的盐，可用于抑制PI3K的δ同种型，以及用于治疗由脂质激酶如炎症，免疫学和癌症介导的病症。公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式